Around one in ten people may carry gene variants that blunt how well GLP-1s work
Awaiting primary-source check
Researchers identified genetic variants associated with reduced response to GLP-1 receptor agonists used in type 2 diabetes, reporting that roughly 10 per cent of the population carries them.
What this actually means
This is the beginning of an answer to a question a lot of people have been asking: why do these drugs work spectacularly for some people and barely at all for others?
If it holds up, it reframes non-response. At the moment someone who loses very little weight on semaglutide is often treated, and often treats themselves, as having failed at it. A genetic explanation makes that a biological fact about them rather than a personal one.
Two cautions. This is a finding about response in type 2 diabetes, not a test you can go and ask for, and it is a long way from changing what anyone is prescribed. And it cuts both ways: it also means nine in ten people do not have this explanation available.
Told first, next time
This story reached you late. A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.